Volume 5.38 | Sep 26

Cord Blood News 5.38 September 26, 2013
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Umbilical Cord and Bone Marrow Mesenchymal Stem Cell Seeding on Macroporous Calcium Phosphate for Bone Regeneration in Rat Cranial Defects
Researchers aimed to investigate human umbilical cord mesenchymal stem cells and human bone marrow mesenchymal stem cells seeding on macroporous calcium phosphate cement, and to compare their bone regeneration in critical-sized cranial defects in rats. [Biomaterials] Abstract
Visit the Human Immunology Portal for cord blood protocols, tips and other resources
PUBLICATIONS (Ranked by impact factor of the journal)
Hypoxia-Induced Therapeutic Neovascularization in a Mouse Model of an Ischemic Limb Using Cell Aggregates Composed of HUVECs and cbMSCs
This work prepared three-dimensional aggregates of human umbilical vein endothelial cells (HUVECs) and cord-blood mesenchymal stem cells (cbMSCs) with different levels of internal hypoxia by a methylcellulose hydrogel system. Scientists found that few apoptosis occurred in these cell aggregates, despite developing a hypoxic microenvironment in their inner cores. [Biomaterials] Abstract

A Novel Extracellular Role for Tissue Transglutaminase in Matrix-Bound Vascular Endothelial Growth Factor-Mediated Angiogenesis
Scientists showed that inhibition of extracellular transglutaminase (TG2) protein crosslinking or downregulation of TG2 expression leads to inhibition of angiogenesis in cell culture, the aorta ring assay and in vivo models. Knockdown of TG2 by short hairpin resulted in inhibition of human umbilical vein endothelial cell migration and tubule formation, which could be restored by adding back wt TG2, but not by the transamidation-defective but GTP-binding mutant W241A. [Cell Death Dis] Full Article

Unrelated Umbilical Cord Blood Transplant for Adult Acute Lymphoblastic Leukemia in First and Second Complete Remission: A Comparison with Allografts from Adult Unrelated Donors
Using Cox regression researchers compared outcomes after 116 mismatched single or double cord blood, 546 peripheral blood progenitor-cells and 140, bone marrow grafts. Patient and disease characteristics of recipients were similar except cord blood recipients were younger, more likely to be non-Caucasians and to have low white blood cell count at diagnosis. [Haematologica] Abstract | Full Article

Gene Expression Modifications in Wharton’s Jelly Mesenchymal Stem Cells Promoted by Prolonged In Vitro Culturing
In order to analyze specific gene expression modifications occurring in Wharton’s Jelly mesenchymal stem cells (WJ-MSCs), along with their culture prolongation, scientists investigated the transcriptomic profiles of WJ-MSCs after four and 12 passages of in vitro expansion by microarray analysis. [BMC Genomics] Full Article

Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients Aged 50 Years or Older with B-Cell ALL in Remission: A Retrospective Study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation
Researchers retrospectively assessed the outcome and pretransplantation predictors of the outcome in 118 patients aged greater than or equal to 50 years who received fludarabine-containing reduced-intensity allo-SCT for B-cell ALL in the first or second CR. Eighty patients received transplants from unrelated donors. [Bone Marrow Transplant] Abstract

Plant Proteolytic Enzyme Papain Abrogates Angiogenic Activation of Human Umbilical Vein Endothelial Cells (HUVEC) In Vitro
It is known that cysteine proteases from plants, like bromelain and papain are capable to suppress inflammatory activation. Recent studies have demonstrated that they may interfere with angiogenesis related pathways as well. The aim of this study was to investigate the anti-angiogenic effects of papain on HUVEC in vitro. [BMC Complement Altern Med] Abstract | Full Article

Register for new mouse/rat HSC CFU training course.
Management of the Refractory Aplastic Anemia Patient: What Are the Options?
The emerging data for alternate donor (cord or haploidentical) transplantation in aplastic anemia has provided additional therapeutic choices to consider in refractory disease. [Blood] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Attend World Stem Cell Summit 2013 in San Diego! Your Window to the World of Regenerative Medicine.
STEMSOFT Announces Release of New Cord Banking Software Solution
STEMSOFT™ Software Inc. (STEMSOFT) announced the release of a new cord banking software solution, STEMSOFT CORD. This new system is like no other cord banking software on the market and offers an intuitive, easy to follow user interface paired with the functionality demanded by this unique workflow. [STEMSOFT Software, Inc.] Press Release

Cord Blood Registry Files Opposition to Americord’s CordAdvantage Mark
Discovery is set to begin in a trademark opposition case brought by Cord Blood Registry against rival private cord blood bank Americord. In the case, which was brought before the Trademark Trial And Appeal Board of the United States Patent and Trademark Office, Cord Blood Registry filed a claim opposing Americord’s use of the trademark application for CordAdvantage, alleging that it infringes upon Cord Blood Registry’s trademark CellAdvantage. [PR Newswire Association LLC] Press Release

Enter Our Contest  
Cord Blood News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
NEW 2013 American Society for Cell Biology Annual Meeting
December 14-18, 2013
New Orleans, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

NEW Postdoctoral Position – Immune Recovery After Hematopoietic Stem Cell Transplantation (University of Minnesota – Twin Cities)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Research Associate – Leukemia & Stem Cell Biology (King’s College London)

Postdoctoral Fellow – Differentiation of Erythrocytes and Endothelial Cells from Hemangioblast (University of Rochester)

Stem Cell Biology Researcher – Human Genetics and Stem Cell Biology (The Czech Genetic Bank Ltd.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Cord Blood News: Archives | Events | Contact Us